论文部分内容阅读
文章简介本研究发现了外泌体介导的lnc ARSR可与内源性RNA mi R-34与mi R-449竞争,促进肾癌对舒尼替尼的药物抵抗,进一步增加了靶基因AXL与c-MET的表达,表明了由外泌体传送的lnc ARSR可以诱导敏感细胞产生耐药抵抗。对恶性程度较高的肾细胞癌而言,舒尼替尼药物抵抗是一个巨大的挑战。在临床治疗中,明确舒尼替尼药
Introduction This study found that exosome-mediated lnc ARSR can compete with endogenous RNA mi R-34 and mi R-449 to promote drug resistance of sunitinib to sunitinib and further increase the target gene AXL and The expression of c-MET indicates that lnc ARSR delivered by exosomes can induce resistance-resistant cells to sensitive cells. Sunitinib’s drug resistance is a huge challenge for more malignant renal cell carcinoma. In clinical treatment, clear sunitinib medicine